ClinicalTrials.gg
RecruitingNCT06187402Updated Sep 9, 2025

A Study of LM-24C5 For Advanced Solid Tumors

A Phase 1/2 interventional study of LM-24C5 in Advanced Solid Tumor, sponsored by LaNova Medicines Limited. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the form (ICF) prior to any study related procedures.
  2. Aged ≥18 years old when sign the ICF, male or female.
  3. (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose.
  4. ≥ 3 months.
  5. Subjects must have histological or cytological confirmation of recurrent or advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
  6. Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples meet the minimum requirements.
  7. At least one according to v1.1.
  8. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
  9. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-24C5.
  2. Any prior treatments towards the target.
  3. Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-24C5, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy, etc. the following treatments have different time limits.
  4. Any adverse event from prior anti-tumor therapy has not yet recovered to≤ grade 1 of v5.0.
  5. Subjects with uncontrolled pain.
  6. Subjects with known central nervous system (CNS) or meningeal .
  7. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
  8. Subjects who experienced grade 3 or higher to the treatment that contains any monoclonal antibody.
  9. Subjects who take systemic (> 10 mg daily prednisone equivalents) or other systemic medications within 2 weeks prior to the first dosing of LM-24C5.
  10. Subjects with the known history of disease.
  11. Subjects with the history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  12. Use of any within 28 days prior to 1st dosing of LM-24C5.
  13. Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin K antagonists for presence of active thromboembolic disease.
  14. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-24C5.
  15. Subjects who have severe cardiovascular disease.
  16. Subjects who have uncontrolled or severe illness, including but not limited to ongoing or active infection
  17. Subjects who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation, or bone marrow transplantation, or autologous hematopoietic stem cell transplantation.
  18. infection, active infection including tuberculosis, and infection, with the exception:
  19. Subjects who have other active which are likely to require the treatment.
  20. female who have positive results in pregnancy test or are lactating.
  21. Subjects who have psychiatric illness or disorders that may preclude study compliance.
  22. Subject who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    LM-24C5 Dose Escalation

    Drug: LM-24C5

  • Experimental
    LM-24C5 Dose Expansion

    Drug: LM-24C5

Interventions

  • DrugLM-24C5

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Phase 1

    Time frame: 60 weeks

  2. Incidence of dose-limiting toxicity (DLT)

    Phase 1

    Time frame: 60 weeks

  3. Incidence of serious adverse event (SAE)

    Phase 1

    Time frame: 60 weeks

  4. Ear Temperature

    Phase 1

    Time frame: 60 weeks

  5. Pulse in BPM(Beat per Minute)

    Phase 1

    Time frame: 60 weeks

  6. Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure)

    Phase 1

    Time frame: 60 weeks

  7. Number of participants with abnormal Hematology test results

    Phase 1

    Time frame: 60 weeks

  8. Number of participants with abnormal Urinalysis test results

    Phase 1

    Time frame: 60 weeks

  9. Number of participants with abnormal Blood Biochemistry test results

    Phase 1

    Time frame: 60 weeks

  10. Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio).

    Phase 1

    Time frame: 60 weeks

  11. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase 1

    Time frame: 60 weeks

  12. 12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.

    Phase 1

    Time frame: 60 weeks

  13. ECOG(Eastern Cooperative Oncology Group) score

    Phase 1

    Time frame: 60 weeks

  14. Overall Response Rate (ORR)

    Phase 2

    Time frame: 36 weeks

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase 1 and 2

    Time frame: 96 weeks

  2. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase 1 and 2

    Time frame: 96 weeks

  3. PK Parameter: Area Under the Concentration-time Curve(AUC)

    Phase 1 and 2

    Time frame: 96 weeks

  4. PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase 1 and 2

    Time frame: 96 weeks

  5. PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Phase 1 and 2

    Time frame: 96 weeks

  6. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase 1 and 2

    Time frame: 96 weeks

  7. PK Parameter: Accumulation Ratio (Rac)

    Phase 1 and 2

    Time frame: 96 weeks

  8. PK Parameter: Elimination Half-life (t1/2)

    Phase 1 and 2

    Time frame: 96 weeks

  9. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase 1 and 2

    Time frame: 96 weeks

  10. PK Parameter: Degree of Fluctuation (DF)

    Phase 1 and 2

    Time frame: 96 weeks

  11. Immunogenicity of LM-24C5

    Phase 1 and 2; Anti-Drug antibody and Nab (if necessary) will be tested.

    Time frame: 96 weeks

  12. Duration of Response (DOR) in Month

    Phase 1 and 2

    Time frame: 96 weeks

  13. Disease control rate (DCR) in percentage

    Phase 1 and 2

    Time frame: 96 weeks

  14. progression-free survival (PFS) in Month

    Phase 1 and 2

    Time frame: 96 weeks

  15. Overall survival (OS) in Month

    Phase 1

    Time frame: 60 weeks

  16. Changes of target lesions from baseline in Millimeter.

    Phase 1 and 2

    Time frame: 96 weeks

  17. Safety: AE/SAE (Number of participants with treatment-related adverse events as assessed by CTCAE v5.0)

    Phase 2

    Time frame: 36 weeks

  18. Ear Temperature

    Phase 2

    Time frame: 36 weeks

  19. Pulse in BPM (Beat per Minute)

    Phase 2

    Time frame: 36 weeks

  20. Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure)

    Phase 2

    Time frame: 36 weeks

  21. Number of participants with abnormal Hematology test results

    Phase 2

    Time frame: 36 weeks

  22. Number of participants with abnormal Urinalysis test results

    Phase 2

    Time frame: 36 weeks

  23. Number of participants with abnormal Blood Biochemistry test results

    Phase 2

    Time frame: 36 weeks

  24. Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio).

    Phase 2

    Time frame: 36 weeks

  25. 12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.

    Phase 2

    Time frame: 36 weeks

  26. ECOG(Eastern Cooperative Oncology Group) score

    Phase 2

    Time frame: 36 weeks

Other outcomes

  1. Relationship between the biomarkers and the anti-tumor activity

    Phase 1 and 2

    Time frame: 96 weeks

07

Study locations

1 of 6 sites recruiting
  • University of Southern California (USC) - Norris Comprehensive Cancer Center
    Los Angeles, California 90089, United States
    Not yet recruiting
    • Heinz-Josef Lenz · Contact
  • Ocala Oncology
    Ocala, Florida 34474, United States
    Recruiting
    • Rama Balaraman · Contact
  • Indiana University Melvan and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
    Not yet recruiting
    • Mateusz Opyrchal · Contact
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
    Not yet recruiting
    • Alex Starodub · Contact
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
    Not yet recruiting
    • Minal Barve · Contact
  • Virginia Cancer Specialists, P.C.
    Fairfax, Virginia 22031, United States
    Not yet recruiting
    • Alexander Spira · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Jun 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Jan 2, 2024
StartActual
Dec 20, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06187402
Responsible party
Sponsor
First posted
Jan 2, 2024
Start date
Dec 20, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 9, 2025

Study contacts

Alex Yuan
Contact
alexyuan@lanovamed.com
+8615901815211
Paul Kong
Contact
paulkong@lanovamed.com
+8613564682439
Terry Pang
study director · LaNova

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion